Researchers at the University of North Carolina have been developing a chemotherapy drug treatment utilizing iontophoresis specifically for prostate and breast cancer. Continue reading
Tag Archives: breast cancer
IND for Clinical Studies of dCellVax Breast Cancer Immune Therapy Filed – Intelligent and Rational Gene Silencing Approach for Cancer
Regen Biopharma recently filed an IND (Investigational New Drug Application) with the FDA to permit the initiation of Phase 1 clinical trials of its dCellVax treatment for advanced breast cancer. Continue reading
Obesity soon to replace tobacco as the number one preventable / treatable cause of cancer
“Obesity is on its way to replacing tobacco as the number one preventable / modifiable cause of cancer,” says Clifford Hudis, MD, the 2013-2014 President of the American Society of Clinical Oncology. Indeed, obese post-menopausal women have up to twice the risk of developing breast cancer as do their normal weight counterparts. Continue reading
Monoclonal antibodies + kinase inhibitors are better than antibodies alone in breast cancer and B-cell lymphoma
The combination of Herceptin plus pan-HER (EGFR and Her 2 an 4) kinase inhibitor neratinib resulted in a 33% improvement in progression free survival versus Herceptin alone in breast cancer patients. Rituxan combined with idelalisib, PI3K inhibitor, resulted in a near doubling of progression-free survival at 24 weeks versus Rituxan, alone in patients with Chronic Lymphocytic Leukemia, non-Hodgkin’s Lymphoma, and small cell lymphoma. The news for neratinib tripled the valuation of Puma Biotechnology, while the FDA granted approval of Gilead’s drug Zydelig (idelalisib). Continue reading
Genentech Acquires Seragon – Selective Estrogen Receptor Degraders for breast cancer
Roche /Genentech announced that it acquired a company called Seragon for its new class of compound – SERD (selective Estrogen Receptor Degraders). Blocking estrogen production (aromatse inhibitors) and the binding to the estrogen receptor (tamoxifen) are mainstays of treatment for patients with ER (estrogen receptor) and PR (progesterone receptor) positive breast cancer. However, patients relapse subsequent to treatment with these agents. Continue reading
Epigenetic signature in blood for breast cancer risk
As reported in Genomic Medicine on June 27, an epigenetic signature in patients with BRCA1 and BRCA2 mutations was found by examining DNA methylation (DNAme) patterns on whole blood samples. Importantly, this signature predicted for a high risk of developing breast cancer even in those patients who did NOT have BRCA1 and BRCA2 mutations. Continue reading